Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 343 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $145.55, for a total value of $49,923.65. Following the sale, the insider now directly owns 156,946 shares in the company, valued at $22,843,490.30. This represents a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
John Fesko also recently made the following trade(s):
- On Thursday, February 6th, John Fesko sold 663 shares of Natera stock. The stock was sold at an average price of $177.77, for a total value of $117,861.51.
Natera Price Performance
Shares of NASDAQ NTRA opened at $144.62 on Wednesday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $19.55 billion, a P/E ratio of -82.17 and a beta of 1.80. The stock has a 50 day moving average of $149.13 and a two-hundred day moving average of $153.04. Natera, Inc. has a twelve month low of $87.20 and a twelve month high of $183.00.
Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.
Analyst Ratings Changes
NTRA has been the topic of several analyst reports. Piper Sandler raised their target price on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Sanford C. Bernstein boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. The Goldman Sachs Group raised their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Finally, Guggenheim increased their price objective on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $175.76.
View Our Latest Report on Natera
Hedge Funds Weigh In On Natera
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Securities Inc. raised its stake in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares during the last quarter. Gladstone Institutional Advisory LLC increased its holdings in shares of Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after purchasing an additional 61 shares during the period. Fulton Bank N.A. raised its stake in shares of Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after purchasing an additional 81 shares during the period. Finally, Silver Oak Securities Incorporated grew its position in Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock valued at $470,000 after buying an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
